[Toxic hepatoses due to Gravistat].

Area of Science:

• Hepatology
• Endocrinology
• Toxicology

Background:

• Oral contraceptives are widely used for ovulation inhibition.
• Toxic hepatosis is a known, albeit rare, adverse effect of some medications.
• Previous instances of liver issues during pregnancy may indicate heightened susceptibility.

Purpose of the Study:

• To explain the relationship between ovulation inhibitors and toxic hepatosis.
• To identify risk factors and contraindications for oral contraceptive use.
• To recommend monitoring protocols for early detection of liver damage.

Main Methods:

• Case study analysis of five patients with toxic hepatosis linked to Gravistat.
• Review of clinical, paraclinical, and histological findings.
• Assessment of patient history for risk factors like jaundice or pruritus during pregnancy.

Main Results:

• Clinical presentation of toxic hepatosis varied among cases.
• Liver damage can occur with initial or subsequent use of ovulation inhibitors.
• History of jaundice in pregnancy or prior toxic hepatosis are significant risk factors.

Conclusions:

• Idiopathic jaundice in pregnancy and prior toxic hepatosis are contraindications for oral contraceptives.
• Monitoring transaminases during the initial three cycles of oral contraceptive use is recommended to detect subclinical liver damage.